关于我们About Us
YeahMed Technology Inc. 注册于美国，是集团的全球主体公司；燕医（上海）科技有限公司由 YeahMed Technology Inc. 100% 持股，作为中国总部承担研发与运营职能。公司主要从事 AI 驱动的生物医药研发与创新驱动的医疗器械研发，目前尚处于初创期，多条研发管线处于早期阶段。 YeahMed Technology Inc., incorporated in the United States, is the global parent entity of the group. YanYi (Shanghai) Technology Co., Ltd. is 100% owned by YeahMed Technology Inc. and serves as the China headquarters for R&D and operations. The company is engaged in AI-driven biopharmaceutical R&D and innovation-driven medical device development. Currently at the startup stage, multiple R&D pipelines are in early phases.
美国主体 YeahMed Technology Inc. 统筹全球战略与资本，聚焦研发落地与产业转化；中国总部燕医（上海）执行中国区研发任务；链接中美两大创新生态。 YeahMed Technology Inc. (US) oversees global strategy and capital, focusing on R&D execution and industrial translation; the China HQ, YanYi (Shanghai), carries out R&D tasks in the China region — bridging the innovation ecosystems of the US and China.
以人工智能与多组学技术重构药物与器械研发流程，用计算能力压缩研发周期、提升管线成功率。 Reshaping drug and device development with AI and multi-omics, compressing R&D cycles and improving pipeline success rates through computation.
创始团队具备一线肿瘤多学科诊疗与临床试验经验，从真实临床痛点出发定义产品方向。 The founding team brings first-hand oncology MDT and clinical trial experience, defining product directions from real clinical pain points.